Oragenics, Inc is developing ONP-002 for concussion and mTBI with patients now dosing in a Phase IIa trial.
Public source
Publisher name
Public post
Kickoff season is officially here, putting renewed attention on concussion and mTBI in professional football. Despite advances in player safety, there is still no FDA-ap…
Company
Oragenics, Inc
We are developing medical technologies that solve unmet clinical needs and have a substantial market opportunity.
- Industry
- Biotechnology
- Location
- Tampa, US
- Company size
- 11–50 employees
About Oragenics, Inc
Every year, 69 million people worldwide sustain a concussion. Not one has access to an FDA-approved pharmacological treatment. Oragenics is a development-stage biopharmaceutical company on a mission to change that. We are developing the first-ever pharmacological treatment for acute concussion — a first-in-class intranasal neurosteroid with a clear FDA regulatory pathway and intellectual property protection through 2040+.
See moreLatest activity
Latest activity from Oragenics, Inc
3 signals
Research & Knowledge
Oragenics, Inc is advancing ONP-002 through clinical development for concussion and mTBI.
Research & Knowledge
Oragenics, Inc is currently in clinical trials for ONP-002, an investigational therapy utilizing a proprietary intranasal delivery platform to explore solutions for mTBI and neuroprotection in vulnerable populations.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Pangea Bio
Pangea Bio announced that the first participant in the Phase 1 first-in-human clinical trial of OT-003, a small-molecule positive allosteric modulator of TrkB, has been dosed.
Research & Knowledge
Ocugen
Ocugen announced that the first patient dosed in its global Phase 3 geographic atrophy clinical trial is advancing the potential of a one-time treatment for life and moving closer to its target of three BLAs by 2028.
Research & Knowledge
BioVie Inc.
BioVie Inc. announced that the last on-treatment patient visit in the ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
Research & Knowledge
Alzamend Neuro
Alzamend Neuro announced that its lead product candidate AL001 uses proprietary ionic cocrystal technology to deliver a therapeutic combination of lithium, proline, and salicylate.
Research & Knowledge
Clearmind Medicine